MENU
+Compare
XBI
ETF ticker: NYSE ARCA
AS OF
Aug 27, 04:59 PM (EDT)
Price
$90.29
Change
+$0.39 (+0.43%)
Net Assets
5.2B

XBI stock forecast, quote, news & analysis

The investment seeks to provide investment results that, before fees and expenses, correspond generally to the total return performance of the S&P Biotechnology Select Industry Index derived from the biotechnology segment of a U... Show more

Category: #Health
XBI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
A.I.Advisor
published price charts
These past five trading days, the ETF lost 0.00% with an average daily volume of 0 shares traded.The ETF tracked a drawdown of 0% for this period.
Interact to see
Advertisement
A.I.Advisor
a Summary for XBI with price predictions
Aug 26, 2025

XBI in +1.91% Uptrend, advancing for three consecutive days on August 22, 2025

Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where XBI advanced for three days, in of 305 cases, the price rose further within the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on August 12, 2025. You may want to consider a long position or call options on XBI as a result. In of 92 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for XBI just turned positive on August 13, 2025. Looking at past instances where XBI's MACD turned positive, the stock continued to rise in of 56 cases over the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 213 cases where XBI Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The 10-day RSI Indicator for XBI moved out of overbought territory on August 18, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 22 similar instances where the indicator moved out of overbought territory. In of the 22 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 65 cases where XBI's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where XBI declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

XBI broke above its upper Bollinger Band on August 13, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are ABBVIE (NYSE:ABBV), Amgen (NASDAQ:AMGN), Gilead Sciences (NASDAQ:GILD), Regeneron Pharmaceuticals (NASDAQ:REGN), Biogen (NASDAQ:BIIB), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Moderna (NASDAQ:MRNA), Exact Sciences Corp (NASDAQ:EXAS), Arrowhead Pharmaceuticals (NASDAQ:ARWR).

Industry description

The investment seeks to provide investment results that, before fees and expenses, correspond generally to the total return performance of the S&P Biotechnology Select Industry Index derived from the biotechnology segment of a U.S. total market composite index. In seeking to track the performance of the S&P Biotechnology Select Industry Index (the "index"), the fund employs a sampling strategy. It generally invests substantially all, but at least 80%, of its total assets in the securities comprising the index. The index represents the biotechnology segment of the S&P Total Market Index ("S&P TMI").

Market Cap

The average market capitalization across the SPDR® S&P Biotech ETF ETF is 9.02B. The market cap for tickers in the group ranges from 125.34M to 368.08B. ABBV holds the highest valuation in this group at 368.08B. The lowest valued company is SCLX at 125.34M.

High and low price notable news

The average weekly price growth across all stocks in the SPDR® S&P Biotech ETF ETF was 20%. For the same ETF, the average monthly price growth was 99%, and the average quarterly price growth was 233%. RCKT experienced the highest price growth at 16%, while NVAX experienced the biggest fall at -21%.

Volume

The average weekly volume growth across all stocks in the SPDR® S&P Biotech ETF ETF was -25%. For the same stocks of the ETF, the average monthly volume growth was -9% and the average quarterly volume growth was -9%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 59
P/E Growth Rating: 78
Price Growth Rating: 56
SMR Rating: 86
Profit Risk Rating: 85
Seasonality Score: -24 (-100 ... +100)
View a ticker or compare two or three
XBI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

Category Health

Profile
Fundamentals
Details
Category
Health
Address
SPDR Series TrustOne Lincoln Street Cph0326Boston
Phone
N/A
Web
www.spdrs.com